Cargando…

Hereditary cancer syndromes

Hereditary cancer syndromes (HCSs) are arguably the most frequent category of Mendelian genetic diseases, as at least 2% of presumably healthy subjects carry highly-penetrant tumor-predisposing pathogenic variants (PVs). Hereditary breast-ovarian cancer and Lynch syndrome make the highest contributi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imyanitov, Evgeny N, Kuligina, Ekaterina S, Sokolenko, Anna P, Suspitsin, Evgeny N, Yanus, Grigoriy A, Iyevleva, Aglaya G, Ivantsov, Alexandr O, Aleksakhina, Svetlana N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993141/ https://www.ncbi.nlm.nih.gov/pubmed/36908677 http://dx.doi.org/10.5306/wjco.v14.i2.40

Ejemplares similares

Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings
por: Kuligina, Ekaterina S., et al.
Publicado: (2021)

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine
por: Sokolova, Tatiana N., et al.
Publicado: (2021)

Cytotoxic and targeted therapy for hereditary cancers
por: Iyevleva, Aglaya G., et al.
Publicado: (2016)

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019)

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
por: Orlov, Sergey V., et al.
Publicado: (2021)

Hereditary Breast-Ovarian Cancer Syndrome in Russia
por: Sokolenko, A.P., et al.
Publicado: (2010)

PALB2 mutations in German and Russian patients with bilateral breast cancer
por: Bogdanova, Natalia, et al.
Publicado: (2010)

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
por: Aleksakhina, Svetlana N., et al.
Publicado: (2021)

Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma
por: Kuligina, Ekaterina, et al.
Publicado: (2021)

Comprehensive evaluation of the test for 5′‐/3′‐end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
por: Imyanitov, Evgeny N., et al.
Publicado: (2020)

Molecular testing for colorectal cancer: Clinical applications
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Markers of Lymphocytic-Macrophagal Infiltration and Their Association With the Receptor Phenotype and Proliferative Activity of Tumor Tissue in Various Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev M, et al.
Publicado: (2021)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

Systemic therapy for hereditary cancer
por: Imyanitov, Evgeny N
Publicado: (2012)

MON-309 Intratumoral Proliferation and Proinflammatory Macrophages in Obese and Non-Obese Patients with Different Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev, et al.
Publicado: (2019)

Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples
por: Romanko, Aleksandr A., et al.
Publicado: (2023)

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
por: Sokolenko, Anna P, et al.
Publicado: (2009)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

SUN-133 Intratumoral Expression of Steroid Receptors, CD68+ Macrophages and Mdm2 in Different Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev M, et al.
Publicado: (2020)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

Molecular Diagnostics in Clinical Oncology
por: Sokolenko, Anna P., et al.
Publicado: (2018)

Drug therapy for hereditary cancers
por: Imyanitov, Evgeny N, et al.
Publicado: (2011)

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
por: Sokolenko, Anna P., et al.
Publicado: (2023)

Systemic treatment for hereditary cancers: a 2012 update
por: Imyanitov, Evgeny N, et al.
Publicado: (2013)

Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
por: Moiseyenko, Fedor V., et al.
Publicado: (2022)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Integrative Genomic Tests in Clinical Oncology
por: Imyanitov, Evgeny, et al.
Publicado: (2022)

Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer
por: Sokolenko, Anna P., et al.
Publicado: (2022)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Cytotoxic and targeted therapy for BRCA1/2-driven cancers
por: Imyanitov, Evgeny N.
Publicado: (2021)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

The role of intradermal proliferation of T-cells in the pathogenesis of psoriasis
por: Khairutdinov, Vladislav R., et al.
Publicado: (2017)

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine
por: Gu, Yuexi, et al.
Publicado: (2016)

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion
por: Moiseyenko, Vladimir M, et al.
Publicado: (2018)

Molecular Analysis of Biliary Tract Cancers with the Custom 3′ RACE-Based NGS Panel
por: Mitiushkina, Natalia V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nau5363c5gkiemqn6bite8cslp